Oaktree Fund Advisors LLC Invests $949,000 in Mesoblast Limited (NASDAQ:MESO)

Oaktree Fund Advisors LLC acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 47,909 shares of the company's stock, valued at approximately $949,000. Mesoblast comprises about 1.6% of Oaktree Fund Advisors LLC's investment portfolio, making the stock its 18th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new stake in Mesoblast in the 4th quarter worth $30,000. Lindbrook Capital LLC increased its stake in Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after acquiring an additional 901 shares during the period. JPMorgan Chase & Co. acquired a new position in Mesoblast in the 4th quarter valued at approximately $50,000. GAMMA Investing LLC grew its holdings in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after purchasing an additional 1,213 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Mesoblast during the fourth quarter valued at approximately $134,000. Institutional investors own 1.43% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on MESO shares. Piper Sandler restated an "overweight" rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a report on Monday. Finally, Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Mesoblast has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Remove Ads

Mesoblast Stock Down 0.4 %

Shares of Mesoblast stock traded down $0.05 during mid-day trading on Thursday, reaching $11.77. 89,758 shares of the stock were exchanged, compared to its average volume of 304,643. Mesoblast Limited has a fifty-two week low of $4.60 and a fifty-two week high of $22.00. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm has a 50-day simple moving average of $15.97 and a 200 day simple moving average of $13.28.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.